<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506856</url>
  </required_header>
  <id_info>
    <org_study_id>GOTIC-001/JGOG3019</org_study_id>
    <secondary_id>UMIN000003670</secondary_id>
    <nct_id>NCT01506856</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial</brief_title>
  <acronym>iPocc</acronym>
  <official_title>A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Trial &amp; Investigation Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japanese Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Trial &amp; Investigation Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

      Phase A: To confirm the feasibility of paclitaxel administered by intravenous (IV) infusion
      weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every
      3 weeks (dd-TCip therapy).

      Phase B: To compare the efficacy and safety of the following two treatment regimens as
      first-line chemotherapy in women with epithelial ovarian, Fallopian tube or primary
      peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multicenter international study. Patient are stratified according to
      Residual tumor diameter([0cm(No residual)] vs. [0cm＜residual＜1cm] vs. [1cm&lt;residual&lt;2cm] vs.
      [&gt;2 cm]), FIGO stage(StageII vs. III vs. IV) and institution. Patient randomized to one of
      the treatment arms described below.

      RegimenI(Standard treatment: dd-TCiv therapy): Paclitaxel administered by IV infusion weekly
      plus concurrent carboplatin administered by IV infusion once every 3 weeks

      RegimenII(Study treatment: dd-TCip therapy): Paclitaxel administered by IV infusion weekly
      plus concurrent carboplatin administered by IP injection once every 3 weeks

      The 3-week period (21 days) is 1 cycle. Protocol treatment basically comprises 6 cycles. IDS
      is allowed to be performed after 3, 4 or 5 cycles of the protocol treatment. In such cases,
      the protocol treatment must be restarted within 8 weeks after IDS. If IDS is performed,
      patients can receive up to 3 additional cycles of the protocol treatment after IDS. If
      interval debulking surgery (IDS) is performed after 3, 4 or 5 cycles, the patients can
      receive up to 3 additional cycles of the protocol treatment. A total of 6 to 8 cycles will be
      repeated.

      The analysis of efficacy will be performed on all randomized subjects in accordance with the
      intention-to-treat (ITT) principle. In order to assess the robustness of the results, the
      same analyses will be done using all randomized subjects who satisfy the eligibility
      criteria. The analysis of safety will be performed on all subjects who have received at least
      one dose of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until 510 events are observed or until 3 years from the last patient is randomized to the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>weekly during the protocl treatment, then every 3 months for the first 2 years, 6-month for the following 2 years, and once a year thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (only patients with evaluable disease)</measure>
    <time_frame>every 2 cycles [after 2 cycles, after 4 cycles, after 6 cycles, (after 8 cycles)], the time of discontinuation of the protocol treatment and then at least annually during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>weekly during the protocl treatment, then every 3 months for the first 2 years, 6-month for the following 2 years, and once a year thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment completion rate</measure>
    <time_frame>After the last cycle of the protocol teatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) assessments</measure>
    <time_frame>baseline, after 3 cycles, 6 cycles, 36 week, 60 weeks and 84 weeks from the start of protocol treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility analysis</measure>
    <time_frame>baseline, after 3 cycles, 6 cycles, 36 week, 60 weeks and 84 weeks from the start of protocol treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">654</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Standard treatment: dd−TCiv therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study treatment: dd-TCip therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel(intravenous) + Carboplatin(intravenous)</intervention_name>
    <description>Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.</description>
    <arm_group_label>Standard treatment: dd−TCiv therapy</arm_group_label>
    <other_name>Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel(intravenous) + Carboplatin(intraperitoneal)</intervention_name>
    <description>Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.</description>
    <arm_group_label>Study treatment: dd-TCip therapy</arm_group_label>
    <other_name>Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients assumed to have a stageII−IV epithelial ovarian, fallopian tube, or primary
             peritoneal cancer as a pre-surgery diagnosis

          2. Patients scheduled to undergo laparotomy

             *Both optimal and suboptimal patients will be eligible for the study (Suboptimal
             patients, as well as those who undergo only exploratory laparotomy, are eligible.)

          3. ECOG Performance Status: 0-2

          4. Patients who provide consent for placement of the IP port system, if randomized to
             Regimen II (Study treatment: dd-TCip therapy)

          5. Patients expected to receive the first protocol treatment within 8 weeks after the
             comprehensive staging surgery

          6. Lab data and clinical examination: Data within 28 days before the scheduled date of
             surgery

               -  Neutrophil count ≧ 1,500 /mm3

               -  Platelet count ≧ 100,000 /mm3

               -  AST (GOT) ≦ 100 IU/L

               -  ALT (GPT) ≦ 100 IU/L

               -  Total bilirubin &lt; 1.5 mg/dL

               -  Serum Creatinine &lt; 1.5 mg/dL

               -  Electrocardiogram (ECG): Patients with normal ECG, Asymptomatic patients with
                  abnormal ECGs not requiring medical intervention

               -  Neuropathy(Both motor and sensory) ≦ Grade1 (CTCAE Version 4.0)

          7. Patients expected to survive longer than 3 months from the start date of the protocol
             treatment

          8. Patients aged 20 years and older at the time of tentative registration (with no upper
             age limit)

          9. Patients who provide written informed consent for participation in this trial

        Exclusion Criteria:

          1. Patients assumed to have a borderline malignancy of the ovary, fallopian tube, or
             primary peritoneal cancer

          2. Patients who have received previous chemotherapy or radiation therapy to treat the
             current disease

          3. Patients who have a synchronous malignancy or who have been progression-free less than
             5 years for a metachronous malignancy (Patients with basal and squamous cell carcinoma
             of the skin, as well as carcinoma in situ, and intramucosal carcinoma cured by local
             treatment, are eligible for the study)

          4. Patients with serious medical complications, such as serious heart disease,
             cerebrovascular accidents, uncontrolled diabetes mellitus, uncontrolled hypertension,
             pulmonary fibrosis, interstitial pneumonitis, active bleeding, an active
             gastrointestinal ulcer, or a serious neurological disorder

          5. Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated
             castor oil

          6. Patients with a pleural effusion requiring continuous drainage

          7. Patients with an active infection requiring antibiotics

          8. Patients who are pregnant, nursing or of child-bearing potential

          9. Patients with evidence upon physical examination of brain tumor and any brain
             metastases

         10. Patients for whom completion of this study and/or follow-up is deemed inappropriate
             for any reason

         11. Patients with any signs/symptoms of interstitial pneumonia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keiichi Fujiwara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Saitama Medical University International Medical Center Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>Pa 15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam Road</city>
        <zip>102</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Kanokoden, Chikusa-ku, Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirosaki University School of Medicine &amp; Hospital</name>
      <address>
        <city>Hirosaki-shi</city>
        <state>Aomori</state>
        <zip>036-8203</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University School of Medicine, Kashiwa Hospital</name>
      <address>
        <city>Kashiwashita, Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Shikoku Cancer Center</name>
      <address>
        <city>Kou160 Minamiumemotomachi, Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>791-0245</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon-shi</city>
        <state>Ehime</state>
        <zip>791-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Matsuokashimoaizuki, Yoshida-gun, Eiheiji-cho</city>
        <state>Fukui</state>
        <zip>910-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Kyusyu Medical center</name>
      <address>
        <city>Jigyohama, Fukuoka-shi Chuo-ku</city>
        <state>Fukuoka</state>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Showamachi, Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Takahayashinishicho, Ota-shi</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Kure Medical Center And Chugoku Cancer Center</name>
      <address>
        <city>Aoyamacho, Kure-shi</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyoshi Central Hospital</name>
      <address>
        <city>Higashisakeyamachi, Miyoshi-shi</city>
        <state>Hiroshima</state>
        <zip>728-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JA Hiroshima General Hospital</name>
      <address>
        <city>Otemachi, Hiroshima-shi Naka-ku</city>
        <state>Hiroshima</state>
        <zip>730-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Society Himeji Hospital</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Minatojimaminamimachi, Kobe-shi Chuo-ku</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Medical College Hospital</name>
      <address>
        <city>Mukogawacho, Nishinomiya-shi</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Amakubo, Tsukuba-shi</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Uchimaru, Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital</name>
      <address>
        <city>Kajiyacho, Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>892-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical University Musasi Kosugi Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Okazawacho, Yokohama-shi Hodogaya-ku</city>
        <state>Kanagawa</state>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Shimokasuya, Isehara-shi</city>
        <state>Kanagawa</state>
        <zip>259-1143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Edobashi, Tsu-shi</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie Prefectural General Medical Center</name>
      <address>
        <city>Hinaga, Yokkaichi-shi</city>
        <state>Mie</state>
        <zip>510-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Seiryocho, Sendai-shi Aoba-ku</city>
        <state>Miyagi</state>
        <zip>980-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Asahi, Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Nagasaki Hospital</name>
      <address>
        <city>Katafuchi, Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>850-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical Univeｒsity Hospital</name>
      <address>
        <city>Shijocho, Kashihara-shi</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Asahimachidori, Niigata-shi Chuo-ku</city>
        <state>Niigata</state>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Kawagishicho, Niigata-shi Chuo-ku</city>
        <state>Niigata</state>
        <zip>951-8133</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okinawa Prefectural Chubu Hospital</name>
      <address>
        <city>Miyazato, Uruma-shi</city>
        <state>Okinawa</state>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Daigakumachi, Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>569-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaizuka City Hospital</name>
      <address>
        <city>Hori, Kaizuka-shi</city>
        <state>Osaka</state>
        <zip>597-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Nakamichi, Osaka-shi Higashinari-ku</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Yamadaoka, Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Saitama Medical Center</name>
      <address>
        <city>Kamoda, Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center</name>
      <address>
        <city>Yamane, Hidaka-shi</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shimonagakubo, Nagaizumi-cho, Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Yakushiji, Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Yonan, Utsunomiya-shi</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital Of JFCR</name>
      <address>
        <city>Ariake, Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <zip>113-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Hatanodai, Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Hongo, Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Daisan Hospital</name>
      <address>
        <city>Izumihoncho, Komae-shi</city>
        <state>Tokyo</state>
        <zip>201-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Medical Center East</name>
      <address>
        <city>Kawadacho, Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital</name>
      <address>
        <city>Nishishinbashi, Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinanomachi, Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori Municipal Hospital</name>
      <address>
        <city>Matoba, Tottori-shi</city>
        <state>Tottori</state>
        <zip>680-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University</name>
      <address>
        <city>Nishicho, Yonago-shi</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Minamikogushi, Ube-shi</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gongneung-Dong</state>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital in Korea</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>250</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center</name>
      <address>
        <city>Yangcheon-gu</city>
        <state>Seoul</state>
        <zip>1071</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinchon Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Otago - Christchurch/Christchurch Women's Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Bukit Timah</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital of Singapore</name>
      <address>
        <city>Lower Kent Ridge Road</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://studyweb.kitasato-ctcc.jp/</url>
    <description>Kitasato Academic Research Organization, Kitasato University</description>
  </link>
  <link>
    <url>http://www.jgog.gr.jp/</url>
    <description>Japanese Gynecologic Oncology Group</description>
  </link>
  <link>
    <url>http://www.gotic.jp/</url>
    <description>Gynecologic Oncology Trial and Investigation Consortium [Japanese only]</description>
  </link>
  <reference>
    <citation>Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59.</citation>
    <PMID>11870167</PMID>
  </reference>
  <reference>
    <citation>Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92.</citation>
    <PMID>10963636</PMID>
  </reference>
  <reference>
    <citation>Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708.</citation>
    <PMID>10793106</PMID>
  </reference>
  <reference>
    <citation>Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14.</citation>
    <PMID>12860964</PMID>
  </reference>
  <reference>
    <citation>Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.</citation>
    <PMID>19767092</PMID>
  </reference>
  <reference>
    <citation>Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5.</citation>
    <PMID>8960474</PMID>
  </reference>
  <reference>
    <citation>Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7.</citation>
    <PMID>11181662</PMID>
  </reference>
  <reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </reference>
  <reference>
    <citation>Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I; Sankai Gynecology Study Group (SGSG). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005 Dec;99(3):591-6. Epub 2005 Aug 10.</citation>
    <PMID>16095677</PMID>
  </reference>
  <reference>
    <citation>Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20. Review.</citation>
    <PMID>17291226</PMID>
  </reference>
  <reference>
    <citation>Demets DL. Futility approaches to interim monitoring by data monitoring committees. Clin Trials. 2006;3(6):522-9. Review.</citation>
    <PMID>17170036</PMID>
  </reference>
  <reference>
    <citation>Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93.</citation>
    <PMID>17362317</PMID>
  </reference>
  <reference>
    <citation>Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56.</citation>
    <PMID>2681557</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>intraperitoneal therapy</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

